...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in lipidology >Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.
【24h】

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.

机译：降胆固醇治疗的药物遗传学和药物基因组学。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: To summarize recent findings on pharmacokinetics, pharmacodynamics, drug-drug interactions and influence of lifestyle heterogeneity on adverse events in cholesterol-lowering therapy RECENT FINDINGS: The prevention of cardiovascular disease is critically dependent on lipid-lowery therapy, including statins, cholesterol absorption inhibitors, fibrates and nicotinic acid. Statins are the most prescribed drugs in lipid lowering therapy with variability in response and almost one third of the patients do not meet their treatment goals. The severe adverse effects of treatment with cerivastatin stimulated the search for new genes and gene variations affecting pharmacokinetics, drug-drug interactions and pharmacodynamics. Moreover, instead of monotherapy, combined therapy of statins with ezetemibe and niacin was considered. This led to the identification of CD13, NPC1L1 and HM74A as new targets and CYP2C8 and glucuronidation enzymes as potential targets for drug-drug interactions. Moreover multiple polymorphic sites and pleiotrophic gene targets were reinvestigated in larger cohorts and the relevant pathogenetic factors start to evolve. SUMMARY: Statin therapy is widely used and well tolerated by the majority of patients. To further reduce potential adverse effects and to increase efficacy, combined therapy concepts with ezetimibe or niacin are underway.
机译：审查目的：总结关于降胆固醇治疗中药物动力学，药效学，药物相互作用以及生活方式异质性对不良事件的影响的最新发现最近发现：心血管疾病的预防严重依赖降脂治疗，包括他汀类药物，胆固醇吸收抑制剂，贝特类药物和烟酸。他汀类药物是降脂治疗中处方最多的药物，其反应具有可变性，几乎三分之一的患者未达到治疗目标。西立伐他汀治疗的严重不良反应刺激了对新基因和影响药物动力学，药物相互作用和药效动力学的基因变异的寻找。此外，考虑到他汀类药物与依泽米贝和烟酸的联合治疗，而不是单一疗法。这导致将CD13，NPC1L1和HM74A鉴定为新的靶标，并将CYP2C8和葡萄糖醛酸苷化酶鉴定为药物相互作用的潜在靶标。此外，在较大的队列中对多个多态性位点和多营养基因靶标进行了重新研究，并且相关的致病因素开始发展。总结：他汀类药物疗法已被大多数患者广泛使用并且耐受性良好。为了进一步减少潜在的不良反应并提高疗效，正在与依泽替米贝或烟酸联合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号